Introduction Learning Objectives Introduction

Introduction

Watch a series of internationally renowned clinical specialists from Europe discuss pivotal data for Parkinson’s disease from key neurology congresses throughout 2018 and consider how these findings may affect clinical practice.

The potential implications of these data for optimizing outcomes for patients with advanced Parkinson’s disease are explored from both global and regional perspectives.

The information in this activity is intended for neurologists, nurses and other healthcare professionals involved in the treatment of patients with Parkinson’s disease.

Learning Objectives

After watching these touchCONGRESS Expert Opinions from key neurology congresses during 2018, you should be able to:

Summarize the latest clinical data for emerging treatment options and treatment delivery systems for the management of motor and non-motor symptoms of Parkinson’s disease.
Discuss the use of biomarkers for the early identification of Parkinson’s disease, and to facilitate the use of neuroprotective agents.
Describe the use of emerging targeted agents and therapeutic strategies to manage treatment side effects and maintain patient quality of life.

Prof. Angelo Antonini

Professor Antonini, director of the Parkinson Unit at the Neurology Clinic in Padua, Italy, provides his expert insight into data presented at key neurology congresses during 2018 and what they may mean for optimizing clinical outcomes for patients with advanced Parkinson’s disease.

Clinical Spotlight

What were the highlights from AAN, EAN, IAPRD or MDS 2018 on deep brain stimulation and what do they mean for patients with Parkinson’s disease?
How do you think deep brain stimulation might change the treatment paradigm for Parkinson’s disease in the long-term?
What were the highlights from AAN, EAN, IAPRD or MDS 2018 describing gait issues, balance and speech problems that emerge in the advanced phase of Parkinson’s disease?
How do you alter your treatment strategy for patients experiencing cognitive decline?
Data showing that patients who experienced mild traumatic brain injury may have a risk of Parkinson’s disease were presented at AAN 2018. What is your opinion of these findings?

About Prof. Angelo Antonini

Angelo Antonini is Director of the Parkinson Unit at the Neurology Clinic in Padua, Director of the Parkinson and Movement Disorders Unit at the research institute for neurorehabilitation San Camillo, Venice and Professor of Neurology at the University of Padua in Italy. He has conducted research into the definition of imaging biomarkers of the dopamine system and associated neurodegenerative processes, as well as the characterization of brain networks in Parkinson’s disease using FDG-PET. His recent research focuses on the pharmacology of dopaminergic medications, neuroimaging as well as cognitive and behavioral aspects of Parkinson’s disease. In addition, he is actively involved in the use of continuous infusion of levodopa and apomorphine infusion, as well as subthalamic nucleus deep brain stimulus for the treatment of motor fluctuations and dyskinesia of complicated Parkinson’s disease patients.

Professor Antonini has published 368 indexed peer-reviewed manuscripts and several book chapters, and he serves as a reviewer for the main medical and neurology journals.

Disclosures: Consultancy and speaker related activities from AbbVie, Bial, Boehringer Ingelheim, Lundbeck, UCB, Zambon. Research grant from Chiesi Pharmaceuticals, Lundbeck, Horizon 2020 – PD_Pal Grant 825785, Ministry of Education University and Research (MIUR) Grant ARS01_01081. He serves as a consultant for Boehringer–Ingelheim for legal cases on pathological gambling.

touchCONGRESS Expert Opinions

Touch Oncology

touchCONGRESS Expert Opinions

Looking back over 2018: what have we learnt about optimizing the treatment of advanced Parkinson’s disease?

Introduction

Learning Objectives

Please feedback on this touchCONGRESS Expert Opinions on the following:
(scale 1-5, 1 strongly disagree; 5 strongly agree).

touchCONGRESS Expert Opinions

LOGIN or REGISTER to access this content

This content is intended only for healthcare professionals.

Please confirm you are a healthcare professional.

Introduction

Learning Objectives

Please feedback on this touchCONGRESS Expert Opinions on the following:(scale 1-5, 1 strongly disagree; 5 strongly agree).

Please feedback on this touchCONGRESS Expert Opinions on the following:
(scale 1-5, 1 strongly disagree; 5 strongly agree).